Large Study of Female Cancer Survivors Highlights Poor Health Behaviors

Article

Following a large survey of more than 22,000 US women, researchers from H. Lee Moffitt Cancer Center, in Tampa, Florida, have concluded that a significant proportion of female cancer survivors have poor health behaviors, compared with women who have not had cancer.

Following a large survey of more than 22,000 US women, researchers from H. Lee Moffitt Cancer Center, in Tampa, Florida, have concluded that a significant proportion of female cancer survivors have poor health behaviors, compared with women who have not had cancer.

The study found that female cancer survivors have poor health behaviors, compared with women who have not had cancer.

They suggest that identification of prevalent cancer-related behavioral risk factors provides an opportunity to boost wellness among women with a previous cancer history. The study was led by clinical psychologist Sarah M. Rausch, PhD, director of integrative medicine at Moffit, and reported in the February issue of the American Journal of Clinical Oncology.

Investigators administered health questionnaires to 19,948 women presenting for screening mammography. A detailed history of health behaviors was available for 18,510 women, and of this group 2,713 (14.7%) had a previous cancer history.

Dr. Rausch and colleagues reported a number of important and statistically significant results: compared with women who did not have a cancer history, cancer survivors were less likely to rate their overall health as "excellent" (13.6% vs 21.5%), to exercise moderately or strenuously (56.5% vs 63.3%), and to use complementary and alternative medicine (57.4% vs 60.2%).

Cancer survivors were more likely to be current smokers (6.3% vs. 5.5%), rate their overall health as "poor" (15.8% vs. 9.1%), and report more weight gain over time. Cervical cancer survivors (n = 370) in particular were most likely to be current smokers (15.7%) and regular alcohol users (71.7%), compared with other survivors. They also reported the largest weight gain (4.9 lbs at 5 years and 13.4 lbs at 10 years). Survivors of ovarian cancer (n = 185) and uterine cancer (n = 262) most frequently reported being obese (41% and 34.4%, respectively).

In conclusion, Dr. Rausch and colleagues wrote that their findings "suggest opportunities for tailored behavioral health risk factor interventions for specific populations of cancer survivors."

Recent Videos
Oncologists are still working on management strategies for neuropathy; a common adverse effect related to chemotherapeutics for ovarian cancer.
Genetic testing information can be used to risk-stratify ovarian cancer survivors for breast cancer, particularly those with BRCA1 or BRCA2 mutations.
Genetic testing for ovarian cancer may help inform treatment decisions for patients with advanced disease, particularly regarding PARP inhibitor use.
Future findings from a translational analysis of the OVATION-2 trial may corroborate prior clinical data with IMNN-001 in advanced ovarian cancer.
Approximately 10% of patients discontinued treatment with avutometinib/defactinib due to toxicity in the phase 2 RAMP 201 trial.
Response rates appeared to be higher with avutometinib plus defactinib vs avutometinib alone in the phase 2 RAMP 201 study.
Patients who respond to avutometinib/defactinib may be maintained on treatment for long periods of time, says Rachel N. Grisham, MD.
Findings from the OVARIO study show that patients with HRR–deficient and BRCA-mutated disease benefitted the most from niraparib/bevacizumab maintenance.
Related Content